Contrave

Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results

...gen, and the results demonstrate the potential for contrave to help patients in their battle against obesity,"...ight loss." Recent Highlights contrave Orexigen announced that the three remaining Phase 3 trials in the contrave Obesity Research, or COR, program met their co-pri...

-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-

...and 17.1%, respectively (ITT, p<0.001). contrave patients in COR-I and COR-II on Contrave32 had mea...le the 18.9% of patients on placebo (p<0.001). contrave patients also showed a 0.6% reduction in HbA1c fro...cerides. Additional analyses indicate that contrave patients experienced reductions in the frequency a...

Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)

...ity with, Contrave, the potential to commercialize contrave and the expected impact of the license agreement w...yses of data from the remaining clinical trials of contrave may produce negative or inconclusive results, or m...al trials may not be predictive of future results; contrave may not receive regulatory approval on a timely ba...

Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer

...mpletion of the remaining three Phase 3 trials for contrave (naltrexone sustained release (SR)/bupropion SR) a...lment, timing and completion of clinical trials of contrave and Empatic, the potential to obtain regulatory approval for, and effectively treat obesity with, contrave and Empatic, and the scope and duration of protect...

Pipeline for New Obesity Therapies is Focus of New Report

...; Solvay / BMS), rosonabant (E-6776; Esteve), AVE-1625 (Sanofi-Aventis), LH-21 (Instituto de Quimica Medica), Qnexa (phentermine / topiramate; Vivus), contrave (bupropion / naltrexone; Orexigen), Empatic (bupropion SR + zonisamide SR; Orexigen), Meridia (sibutramine; Abbott), lorcaserin (APD356; Arena), Byett...

Contrave in Medical Technology

Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23

SAN DIEGO, June 21, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of central nervous system disorders with an initial focus on obesity, today announced that the Company will present data about its lead obesity product candidat...

Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results

..., a biopharmaceutical company focused on the treatment of obesity, plans to announce the results of the three remaining Phase 3 clinical trials in the contrave program on Monday, July 20, 2009 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern...

Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team

...nticipates announcing the results from the first Phase 3 clinical trial for contrave in January. About Orexigen Therapeutics Orexigen Therapeuti...ng, execution, completion and announcement of results of clinical trials of contrave and the potential to obtain regulatory approval for, and effectively treat ...

Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)

...ne SR, pooled 24 week data from the Phase 2 NB-201 contrave trial (N=212) with naltrexone IR was compared with...24 week blinded data from a series of four Phase 3 contrave trials (N=3,943 evaluable patients), all employing...dverse event (13.8% versus 16.0%). -- Across the contrave Phase 3 trial experience to date, only 7.6% of all...

Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule

... compared to the legacy naltrexone IR formulation. contrave currently is being studied in four Phase III clini...r, and effectively treat obesity with, Empatic and contrave and the enrollment, timing and completion of clinical trials of contrave and Empatic. The inclusion of forward-looking stat...

Contrave in Biological Technology

Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions

...ating control experienced by patients treated with contrave versus placebo (p< 0.01), as well as previously...f cardiometabolic risk. "NB-302 results show that contrave initiates and sustains weight loss and can improve...due to its unique effects on brain reward centers, contrave may allow patients to better control their eating ...

Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy

...s and commercialization strategy for lead products contrave (naltrexone sustained release (SR)/bupropion SR), ... approval for, and effectively treat obesity with, contrave or Empatic. The inclusion of forward-looking stat...luding, without limitation: the clinical trials of contrave may produce negative or inconclusive results, or m...

Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results

...re collecting the last of our patient data for the contrave Phase 3 development program. We believe that if the data is positive, contrave should have the ability to address a tremendously ...lso a director of AMAG Pharmaceuticals, Inc. contrave The...

Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program

... his role, Dr. Scaife will lead the development of contrave (naltrexone sustained release (SR)/bupropion SR), ...luding, without limitation: the clinical trials of contrave may produce negative or inconclusive results, or m...al trials may not be predictive of future results; contrave may not receive regulatory approval on a timely ba...

Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints

...hly statistically significant (p<0.001). contrave was generally well tolerated by patients. The overall safety profile of contrave was consistent with its individual components, nal...ely in patients for over 20 years. Treatment with contrave was not associated with increases in symptoms of d...

Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)

.../Cowley methods patent will provide protection for contrave through mid 2024. "The issuance of this pat...operty coverage." About Contrave(R) contrave is an investigational oral weight loss medication ...wn as the reward center). In fact, we believe that contrave may be the first treatment for obesity to target t...

Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results

...elopment expenses in connection with the Company's contrave Phase 3 clinical trials, related proprietary produ... important results from our lead obesity programs, contrave and Empatic. We are eagerly awaiting data from our...ieve that we remain on track for an NDA filing for contrave in late 2009." Recent Highlights -- Orexigen i...